

Kielpin, 04 April 2018

Purchaser:

Celon Pharma S.A.

Mokra 41A

05-092 Łomianki / Kielpin

tel.: +48 22 751 74 78

fax: +48 22 751 74 77

e-mail:  paulina.gruszka@celonpharma.com

CPV Code: 73100000-3

National Court Register number (KRS): 0000437778

Tax ID number (NIP): 118 - 16 - 42 - 061

REQUEST FOR QUOTATION (RfQ) no. 25/2018/G/CELONKO/Z9

In relation to the planned implementation of the project Development of novel biomarkers and innovative FGFR kinases inhibitor as an anti-cancer therapy by Celon Pharma S.A. as part of the 2nd edition of the contest in the research and development program Prevention and treatment of civilization diseases - STRATEGMED (hereinafter "the Project"), we hereby request your quotation for:

Subcontracting: testing of a single compound in a panel of human primary cells' cocultures:

- **Human primary cell-based systems** constructed with one or more primary cell types from healthy human donors, with added stimuli (such as cytokines or growth factors) to capture relevant signaling networks that naturally occur in human tissue or pathological conditions.
- Systems should be optimized to model in vitro complex human tissue and disease biology of the, for example: vasculature, skin, lung and inflammatory tissues and should be able to define mechanisms of toxicity and to develop predictive signatures of toxicity.
- Systems should allow quantitative measurements of biomarker activities/mount, in example, but not limited to: cell surface receptors, cytokines, chemokines, matrix molecules, enzymes, proliferation and cell toxicity.
- Systems should allow comparative analysis with the biological activities of known bioactive agents in the reference database to predict the safety, efficacy and function of tested compounds.
- The requested minimal number of cell systems tested is 10, minimal number of concentrations tested is 4.

The experiment is planned for 1 compound. The order reserves the right to change the number of testing compounds.

The study will be ordered between April 2018 and December 2018 based on a purchase order prepared by client.

Celon Pharma S.A.

Biuro główne: Ogrodowa 2A, Kielpin
05-092 Łomianki, Polska
telefon: +48 22 751 59 33
fax: +48 22 751 44 58
e-mail: info@celonpharma.com

Organ rejestrujący: Sąd Rejonowy dla Miasta Stołecznego Warszawy w Warszawie
XIV Wydział Gospodarczy Krajowego Rejestru Sądowego
Prezes Zarządu: Maciej Wieczorek
KRS; 0000437778
Kapitał zakładowy: 4 500 000 PLN
NIP: 118 - 16 - 42 - 061
www.celonpharma.com

Address and date for submitting the bids:

1. Bids must be submitted by electronic mail to paulina.gruszka@celonpharma.com
2. Bid must be submitted by the **11th of April 2018** at the latest.
3. Bids submitted after the aforementioned date will not be considered.
4. Bids will be evaluated at the Purchaser's office within 7 days from submission deadline.
5. The final decision will be communicated to all Bidders by electronic mail within 7 days from submission deadline.
6. For further information on the Project, please contact Aleksandra Stanczak, e-mail: aleksandra.stanczak@celonpharma.com

Presentation of the bids:

1. Each Bidder may submit only one bid.
2. The bid must contain the date of preparation, the Bidder's address, telephone number, email address, tax ID number.
3. The bid must be valid until the end of the year 2018.
4. The bid must contain:
 - if submitted by a Bidder operating in Poland, the gross and net bid price and due VAT offered for delivery of the subject of the order on accordance with the requirements set forth herein,
 - if submitted by a Bidder operating outside Poland, the net bid price and information that not VAT or other taxes have been included in the price quotation.
5. The bid should contain the RfQ no. in the title. The RfQ no. must also appear in the titles of invoices.

Note:

1. **This project is currently under evaluation by The National Centre for Research and Development as a part of funding competition therefore Purchaser reserves the right to cancel the order in case of non-co-financing.**
2. The Purchaser will place the order with the bidder whose bid meets all the requirements set forth in this RfQ and is deemed the best relative to the selection criteria set forth herein.
3. The Purchaser reserves the right to close the bidding process without selecting the successful Bidder. In such case the purchaser doesn't need to specify its reasons for doing so.
4. In the course of evaluation and assessment of the bids, the Purchaser may request that the bidders provide clarifications regarding their bids.
5. The bidder may alter or withdraw its offer before the submission deadline.
6. Bids submitted past the submission deadline will not be considered.
7. Bids that do not meet the formal requirements set forth herein will not be considered.
8. The Purchaser does not accept variant bids.
9. The Purchaser does not accept partial bids.
10. The Purchaser permits rejecting bids whose essential content clearly raises reasonable doubts.

The quote will be selected based on the following criteria:

Celon Pharma S.A.

Biuro główne: Ogrodowa 2A, Kielpin
05-092 Łomianki, Polska
telefon: +48 22 751 59 33
fax: +48 22 751 44 58
e-mail: info@celonpharma.com

Organ rejestrujący: Sąd Rejonowy dla Miasta Stołecznego Warszawy w Warszawie
XIV Wydział Gospodarczy Krajowego Rejestru Sądowego
Prezes Zarządu: Maciej Wieczorek
KRS; 0000437778
Kapitał zakładowy: 4 500 000 PLN
NIP: 118 – 16 – 42 – 061
www.celonpharma.com

1. Price – (max. 10 points – this is 50% of the maximum number of points to gain). The points will be awarded as follows: The lowest offered price will be considered 100% and awarded maximal number of points (10 points). The points for consequent offers will be given based on the formula:

$$\frac{Price_{lowest}}{Price_{service}} \times 10 \text{ pts}$$

where:

Price_{lowest} – lowest price amongst offers.

Price_{service} – price proposed in evaluated offer.

2. Number of tested coculture systems – (maximally a total of 5 points – this is 25% of the maximum number of points to gain). Scoring in this criterion will be given as follows: the highest number of tested systems in the proposed study will be considered 100%, and will be given the maximum number of points. Offers with lower number of tested systems will be scored proportionally, according to formula:

$$score = \frac{\text{offered number of systems}}{\text{maximal number of systems}} * 5 \text{ points}$$

3. Number of declared endpoints/readouts – (maximally a total of 5 points – this is 25% of the maximum number of points to gain). Scoring in this criterion will be given as follows: the highest number of declared readouts in the proposed study will be considered 100%, and will be given the maximum number of points. Offers with lower number of tested systems will be scored proportionally, according to formula:

$$score = \frac{\text{offered number of readouts}}{\text{maximal number of readouts}} * 5 \text{ points}$$

4. Total scoring will be considered as a sum of Price, Number of coculture systems and Number of declared endpoints/readouts (20 points maximally to gain).

Celon Pharma S.A.

Biuro główne: Ogrodowa 2A, Kielpin
05-092 Łomianki, Polska
telefon: +48 22 751 59 33
fax: +48 22 751 44 58
e-mail: info@celonpharma.com

Organ rejestrujący: Sąd Rejonowy dla Miasta Stołecznego Warszawy w Warszawie
XIV Wydział Gospodarczy Krajowego Rejestru Sądowego
Prezes Zarządu: Maciej Wieczorek
KRS; 0000437778
Kapitał zakładowy: 4 500 000 PLN
NIP: 118 - 16 - 42 - 061
www.celonpharma.com